Curves of progression-free survival (PFS) and overall survival (OS) estimated using a Bayesian multi-state network meta-analyis (NMA). PFS is the duration of time a patient is alive without disease progression and OS is the duration of a time a patient is alive.

mstate_nma_pfs

mstate_nma_os

Format

A data.table with the following columns:

line

Line of treatment. Either first or second.

mutation

At 2nd line, equal to 1 if there is a T790M mutation and 0 otherwise.

model

The statistical model.

tx_name

Name of the treatment.

month

Trial month.

mean

Mean PFS/OS from the posterior distribution.

median

Median PFS/OS from the posterior distribution.

l95

Lower limit of 95 percent credible interval from posterior distribution.

u95

Upper limit of the 95 percent credible interval from the posterior distribution.

See also

Examples

head(mstate_nma_pfs)
#> line mutation model tx_name month mean median l95 #> 1: 1 NA Weibull erlotinib 0 1.0000000 1.0000000 1.0000000 #> 2: 1 NA Weibull erlotinib 1 0.9813128 0.9831876 0.9591186 #> 3: 1 NA Weibull erlotinib 2 0.9584437 0.9612476 0.9197846 #> 4: 1 NA Weibull erlotinib 3 0.9325516 0.9361429 0.8820475 #> 5: 1 NA Weibull erlotinib 4 0.9043601 0.9075891 0.8382485 #> 6: 1 NA Weibull erlotinib 5 0.8744189 0.8774188 0.7935833 #> u95 #> 1: 1.0000000 #> 2: 0.9931107 #> 3: 0.9808260 #> 4: 0.9653296 #> 5: 0.9478870 #> 6: 0.9284482
head(mstate_nma_os)
#> line mutation model tx_name month mean median l95 #> 1: 1 NA Weibull erlotinib 0 1.0000000 1.0000000 1.0000000 #> 2: 1 NA Weibull erlotinib 1 0.9990851 0.9993163 0.9969418 #> 3: 1 NA Weibull erlotinib 2 0.9971186 0.9975396 0.9926917 #> 4: 1 NA Weibull erlotinib 3 0.9940580 0.9946105 0.9867761 #> 5: 1 NA Weibull erlotinib 4 0.9898799 0.9905707 0.9786638 #> 6: 1 NA Weibull erlotinib 5 0.9845798 0.9853897 0.9697365 #> u95 #> 1: 1.0000000 #> 2: 0.9998248 #> 3: 0.9992038 #> 4: 0.9980502 #> 5: 0.9962049 #> 6: 0.9936172